Ani Pharmaceuticals (ANIP) EBT (2011 - 2026)

Ani Pharmaceuticals has disclosed EBT across 16 years of filings, most recently posting $37.1 million for Q2 2026.

• In Q2 2026, EBT rose 252.47% year-over-year to $37.1 million; the TTM figure through Jun 2026 stood at $142.6 million (up 1066.89% YoY), while the FY2025 annual figure was $95.8 million, up 531.26% from the prior year.
• EBT came in at $37.1 million for Q2 2026 at Ani Pharmaceuticals, down from $40.2 million in the prior quarter.
• In the past five years, EBT ranged from a high of $40.2 million in Q1 2026 to a low of -$31.5 million in Q3 2024.
• Average EBT over 5 years is $6.0 million, with a median of $3.7 million recorded in 2023.
• Year-over-year, EBT slumped 26000.0% in 2022 and surged 1051.59% in 2024.
• Over 5 years, EBT stood at -$5.7 million in 2022, then jumped by 116.53% to $947000.0 in 2023, then sank by 1553.22% to -$13.8 million in 2024, then surged by 328.74% to $31.5 million in 2025, then climbed by 17.85% to $37.1 million in 2026.
• Per Business Quant data, the three most recent EBT figures were $37.1 million in Q2 2026, $40.2 million in Q1 2026, and $31.5 million in Q4 2025.